Nurix Therapeutics, Inc. Common stock Share Price
NASDAQ: NRIX | Mid CapNurix Therapeutics, Inc. Common stock Stock Performance
Open $25.34 | Prev. Close $25.52 | Circuit Range N/A |
Day Range $25.16 - $26.03 | Year Range $8.20 - $26.03 | Volume 39,315 |
Average Traded $25.71 |
Nurix Therapeutics, Inc. Common stock Share Price Today
As of 11 August 2026, Nurix Therapeutics, Inc. Common stock's share price is $25.87. The stock opened at $25.34, compared to its previous close of $25.52. During today's trading session, Nurix Therapeutics, Inc. Common stock's share price traded between $25.16 and $26.03, with an average price of $25.60. Over the past 52 weeks, the stock has recorded a high of $26.03 and a low of $8.20. In terms of performance, Nurix Therapeutics, Inc. Common stock's share price has risen by 61.84% over the last six months and is up 177.13% on a year-on-year basis.
Nurix Therapeutics, Inc. Common stock Share Price Chart
Nurix Therapeutics, Inc. Common stock Stock Fundamentals & Key Indicators
Market Cap $2.24B | PE Ratio (TTM) -8.48 | Dividend Yield N/A |
EPS (TTM) $-3.05 | Revenue (TTM) $83.98M | Return On Equity (TTM) -49.09% |
Profit Margin -314.90% | Debt to Equity 0.16 | Quarterly Earnings Growth YoY -54.70% |
Nurix Therapeutics, Inc. Common stock Quarterly Profit & Loss
All figures in USD
Nurix Therapeutics, Inc. Common stock Annual Profit & Loss
All figures in USD
About Nurix Therapeutics, Inc. Common stock
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Nurix Therapeutics, Inc. Common stock Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $23.00 | $25.52 | +10.05% |
Jul 2026 | $24.52 | $23.19 | -4.33% |
Jun 2026 | $17.43 | $24.24 | +36.60% |
May 2026 | $16.59 | $17.75 | +6.26% |
Apr 2026 | $16.05 | $16.70 | +7.81% |
Mar 2026 | $15.45 | $15.49 | -3.10% |
Feb 2026 | $16.28 | $15.98 | -3.27% |
Jan 2026 | $18.89 | $16.52 | -13.21% |
Dec 2025 | $17.22 | $19.04 | +7.63% |
Nov 2025 | $12.93 | $17.69 | +36.60% |
Oct 2025 | $9.57 | $12.95 | +39.92% |
Sep 2025 | $9.29 | $9.26 | -0.86% |
NRIX Share Price FAQs
What is Nurix Therapeutics, Inc. Common stock share price today?
What is the 52 week high and 52 week low of Nurix Therapeutics, Inc. Common stock stock?
What is NRIX's market capitalisation today?
What is NRIX's net income for the last quarter?
What is the 5 year returns of NRIX?
What is the high & low stock price of NRIX today?
Can I buy NRIX shares in India?